Non Hodgkin Lymphoma Clinical Trial
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
Summary
A non-myeloablative treatment strategy and uniform selection criteria will enable patients with a variety of low grade B-Cell malignancies to attain long term disease control without unacceptably high treatment related mortality.
Full Description
Non myeloablative transplant aims to achieve the immunological advantage of graft versus tumor effect as conventional myeloablative therapy without causing high treatment related toxicities. Non myeloablative transplant has been gaining wider acceptance as a way to achieve longer disease free and over all survival in patients with low grade B-cell malignancies, which otherwise is an incurable disease. Recent studies of non-myeloablative HSCT have demonstrated the powerful effect of graft versus leukemia alone against myeloma and other malignant B-cell malignancies if the transplant is performed for low grade, low volume disease.
Eligibility Criteria
Inclusion Criteria:
Stage II or III non-progressive disease Multiple Myeloma.
CLL/SLL, and low grade Hodgkin Lymphomas that are in a very good partial response or complete response with non-progressive disease.
≤ 70 years old.
Eligible and willing HLA matched related donor.
Bilirubin <2xULN.
ALT and AST <3xULN.
LVEF > 40%.
Creatinine Clearance >40mL/min.
Pulmonary function DLCO corrected to ≥ 70%.
Minimum performance score of 70%.
Platelet count >130 x103 micro L.
LDH ≤1.5xULN.
No proceeding co-morbid condition that significantly increases the risk of severe regimen related toxicity.
No uncontrolled infections.
Exclusion Criteria:
Age >70 years old.
Performance status <70%.
Uncontrolled infections or is HIV positive
Prior malignancies that are felt to have a <80% probability of being cured.
Pregnant, breastfeeding, or refuse to use contraceptive techniques during and for 12 months following transplant.
Prior Allograft
History of rapidly growing disease at diagnosis or at any progression or have MDS.
No eligible and willing HLA matched donor.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Birmingham Alabama, 35249, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.